Mycophenolate vs azathioprine in lupus maintenance
Prevent lupus relapse after induction: compare mycophenolate vs azathioprine using 2024 ACR/EULAR guidance, trial data, pregnancy safety & monitoring tips.
Methotrexate — why it remains the anchor DMARD after 40 years
Why methotrexate remains RA’s anchor after 40 years: proven inflammation control, low cost, predictable monitoring, and room to escalate safely.
Seronegative RA — diagnosis, prognosis, and treatment considerations
RF/anti-CCP negative? Learn how seronegative RA is diagnosed with 2010 criteria, imaging, and treat-to-target care—avoid mimics, missed synovitis, DMARD delays.
Lupus Fatigue: Why It Happens and What Helps
Fatigue is one of the most common and most debilitating symptoms reported by patients with systemic lupus erythematosus (SLE). Unlike
RA vs Osteoarthritis: Understanding the Difference
Joint pain is one of the most common reasons patients seek medical care — and one of the most frequently
Distinguishing inflammatory from non-inflammatory arthritis in primary care
Spot inflammatory arthritis early: 6 referral clues, 30–60+ min morning stiffness, boggy synovitis, focused labs and imaging to prevent joint damage sooner.
Hydroxychloroquine dosing and retinal toxicity — the updated guidance
Dose hydroxychloroquine safely with the 5 mg/kg actual-weight rule, retinal toxicity risk stats, OCT screening timing, and tips to protect lupus control well.
ANCA vasculitis remission induction — cyclophosphamide vs rituximab
Choose rituximab or Cytoxan for ANCA vasculitis with confidence: compare RAVE/RITUXVAS data, relapse, renal-lung urgency, fertility and toxicity tradeoffs.
Subclinical synovitis on ultrasound — clinical relevance or overreach?
Ultrasound can spot subclinical synovitis in RA—but ARCTIC shows why Doppler findings alone shouldn’t trigger escalation. Learn when imaging helps most.
JAK inhibitors vs biologics in RA: how to frame the risk conversation
Choosing JAK inhibitors vs biologics in RA? Weigh FDA boxed warnings, age, heart risk, smoking, cancer and clot history for clearer shared decisions in practice